Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009148 · ClinicalTrials.gov registry record
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
A clinical trial of BRIP1 Gene Mutation and MLH1 Gene Mutation, sponsored by NYU Langone Health.
- Active
- Registry status
- 118
- Enrollment target
- 1
- Study location
NCT04009148: Active study of BRIP1 Gene Mutation and MLH1 Gene Mutation, sponsored by NYU Langone Health.
NCT04009148 is a study of BRIP1 Gene Mutation and MLH1 Gene Mutation that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 118 participants, below the 1,042-participant average among 3 other BRIP1 Gene Mutation trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04009148, a study of BRIP1 Gene Mutation and MLH1 Gene Mutation, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.
Primary Outcome
Number of relatives with successful cascade testing
Conditions Studied
Interventions
- OTHER CASCADE genetic screening
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2027-04-23 |
What the registry record for NCT04009148 still lists
NCT04009148 is an observational study that tracks outcomes without assigning an intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 1,042-participant average among 3 other BRIP1 Gene Mutation trials with a reported enrollment target (89% lower).
The record links to 8 conditions, with BRIP1 Gene Mutation appearing as the primary indexed condition, and to 1 intervention - of which CASCADE genetic screening is the first listed.
NCT04009148 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04009148 about?
NCT04009148 is a clinical study titled "Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome". Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable info...
What is the current status of trial NCT04009148?
This trial is currently active not recruiting. The enrollment target is 118 participants. The study started on 2019-03-01. Estimated completion is 2027-04-23.
What conditions does trial NCT04009148 study?
This clinical trial studies the following conditions: BRIP1 Gene Mutation, MLH1 Gene Mutation, RAD51C Gene Mutation, BRCA-Mutated Ovarian Carcinoma, MSH2 A636P.
What interventions are being tested in trial NCT04009148?
The interventions under investigation include: CASCADE genetic screening (OTHER).
Who is sponsoring clinical trial NCT04009148?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04009148 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRIP1 Gene Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
RECRUITING · NA
-
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
ACTIVE NOT RECRUITING · Phase 2
-
Olaparib In Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI